This “Peanut Allergy - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Peanut Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Peanut Allergy: Understanding
Peanut Allergy: Overview
Peanut allergy is one of the most common and potentially life-threatening food allergies, typically beginning in early childhood and often persisting throughout life. It is triggered by an immune hypersensitivity to peanut proteins, with reactions ranging from mild symptoms to severe anaphylaxis. While strict avoidance is the standard preventive measure, the widespread presence of trace peanut residues in food makes complete elimination challenging, particularly for children. Due to its severity and prevalence, peanut allergy has become a major focus of research, leading to the development of immunotherapies and vaccine-based strategies aimed at inducing tolerance and improving patient safety.
Peanut allergy symptoms can range from mild to severe, often appearing within minutes to hours after exposure. Mild to moderate symptoms include skin reactions such as hives, redness, or itching, digestive issues like nausea and abdominal pain, respiratory symptoms such as sneezing, wheezing, and throat tightness, and oral symptoms like tingling or swelling in the lips and mouth. Severe reactions can lead to anaphylaxis, marked by difficulty breathing, low blood pressure, loss of consciousness, and swelling of the throat or tongue, requiring immediate treatment with epinephrine. Because reactions can vary in severity and unpredictability, individuals with peanut allergy should avoid all peanut-containing products, consult an allergist, and carry an epinephrine auto-injector at all times.
Peanut allergy is classified as a type I IgE-mediated hypersensitivity reaction. During initial sensitization, exposure to peanut proteins stimulates the immune system to produce peanut-specific IgE antibodies, primarily targeting allergens such as Ara h 1, h 2, and h 3. Upon re-exposure, these antibodies bind to IgE receptors on mast cells and basophils, leading to the release of histamine and other inflammatory mediators that drive the allergic response. Peanut allergens are low molecular weight proteins that are notably resistant to heat, enzymatic digestion, and denaturation, contributing to their potent immunogenicity. To date, eleven distinct peanut allergens (Ara h 1-11) have been identified.
The primary management strategy for peanut allergy remains strict avoidance of peanut-containing foods, though severe reactions such as anaphylaxis can still occur unintentionally. Epinephrine is the first-line treatment for anaphylaxis and should be administered intramuscularly in the lateral thigh, with intravenous administration reserved for monitored settings. Adjunctive treatments like antihistamines, corticosteroids, and bronchodilators may help alleviate symptoms but do not replace epinephrine. Emerging therapies aim to induce desensitization and tolerance, including oral immunotherapy (OIT), epicutaneous immunotherapy, sublingual immunotherapy, mutated peanut proteins, and plasmid DNA vaccines. These approaches offer promising alternatives to improve safety and quality of life for individuals with peanut allergy.
"Peanut Allergy - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peanut Allergy pipeline landscape is provided which includes the disease overview and Peanut Allergy treatment guidelines. The assessment part of the report embraces, in depth Peanut Allergy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peanut Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Peanut Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Peanut Allergy.
Peanut Allergy Emerging Drugs Chapters
This segment of the Peanut Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peanut Allergy Emerging Drugs
Peanut Allergy: Therapeutic Assessment
This segment of the report provides insights about the different Peanut Allergy drugs segregated based on following parameters that define the scope of the report.
Major Players in Peanut Allergy
The report covers around 12+ products under different phases of clinical development, like:
Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:
Products have been categorized under various Molecule types, such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Peanut Allergy: Pipeline Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Peanut Allergy therapeutic drugs key players involved in developing key drugs.
Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peanut Allergy drugs.
Peanut Allergy Report Insights
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Peanut Allergy: Understanding
Peanut Allergy: Overview
Peanut allergy is one of the most common and potentially life-threatening food allergies, typically beginning in early childhood and often persisting throughout life. It is triggered by an immune hypersensitivity to peanut proteins, with reactions ranging from mild symptoms to severe anaphylaxis. While strict avoidance is the standard preventive measure, the widespread presence of trace peanut residues in food makes complete elimination challenging, particularly for children. Due to its severity and prevalence, peanut allergy has become a major focus of research, leading to the development of immunotherapies and vaccine-based strategies aimed at inducing tolerance and improving patient safety.
Peanut allergy symptoms can range from mild to severe, often appearing within minutes to hours after exposure. Mild to moderate symptoms include skin reactions such as hives, redness, or itching, digestive issues like nausea and abdominal pain, respiratory symptoms such as sneezing, wheezing, and throat tightness, and oral symptoms like tingling or swelling in the lips and mouth. Severe reactions can lead to anaphylaxis, marked by difficulty breathing, low blood pressure, loss of consciousness, and swelling of the throat or tongue, requiring immediate treatment with epinephrine. Because reactions can vary in severity and unpredictability, individuals with peanut allergy should avoid all peanut-containing products, consult an allergist, and carry an epinephrine auto-injector at all times.
Peanut allergy is classified as a type I IgE-mediated hypersensitivity reaction. During initial sensitization, exposure to peanut proteins stimulates the immune system to produce peanut-specific IgE antibodies, primarily targeting allergens such as Ara h 1, h 2, and h 3. Upon re-exposure, these antibodies bind to IgE receptors on mast cells and basophils, leading to the release of histamine and other inflammatory mediators that drive the allergic response. Peanut allergens are low molecular weight proteins that are notably resistant to heat, enzymatic digestion, and denaturation, contributing to their potent immunogenicity. To date, eleven distinct peanut allergens (Ara h 1-11) have been identified.
The primary management strategy for peanut allergy remains strict avoidance of peanut-containing foods, though severe reactions such as anaphylaxis can still occur unintentionally. Epinephrine is the first-line treatment for anaphylaxis and should be administered intramuscularly in the lateral thigh, with intravenous administration reserved for monitored settings. Adjunctive treatments like antihistamines, corticosteroids, and bronchodilators may help alleviate symptoms but do not replace epinephrine. Emerging therapies aim to induce desensitization and tolerance, including oral immunotherapy (OIT), epicutaneous immunotherapy, sublingual immunotherapy, mutated peanut proteins, and plasmid DNA vaccines. These approaches offer promising alternatives to improve safety and quality of life for individuals with peanut allergy.
"Peanut Allergy - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peanut Allergy pipeline landscape is provided which includes the disease overview and Peanut Allergy treatment guidelines. The assessment part of the report embraces, in depth Peanut Allergy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peanut Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Peanut Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Peanut Allergy.
Peanut Allergy Emerging Drugs Chapters
This segment of the Peanut Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peanut Allergy Emerging Drugs
DBV712: DBV Technologies
DBV712 is an investigational epicutaneous immunotherapy (EPIT) product developed by DBV Technologies for the treatment of peanut allergy. It consists of a patch that delivers microgram amounts of peanut protein through the skin, aiming to desensitize the immune system over time and reduce allergic reactions upon accidental exposure. DBV712 is designed for daily application on the back, leveraging the skin’s immune properties to induce tolerance with a favorable safety profile. This non-invasive approach offers a convenient alternative to oral immunotherapy, particularly for pediatric patients. Currently, the drug is in Phase III stage of its development for the treatment of Peanut Allergy.PVX-108: Aravax Pty Ltd
PVX108 comprises a mixture of peptides that represent sequences from peanut allergens which are critical for recognition by peanut-specific T cells. Unlike other peanut allergy immunotherapies, PVX108 does not contain the peanut proteins (allergens) which cause severe allergic reactions. PVX108 is being developed as a safe and simple therapy to restore and maintain tolerance, and reduce the risk of severe allergic reactions upon accidental exposure to peanuts. PVX108 therefore offers several advantages over other approaches. It has negligible risk of activating basophils and mast cells in people with peanut allergy. It does not require careful dose escalation or daily administration. It retrains the immune system to restore and maintain tolerance, reducing the risk of anaphylaxis. PVX108 does not contain natural extracts or whole allergens and has been engineered to be incapable of triggering acute allergic reactions. It has been designed to provide a safe, convenient and long-lasting treatment with monthly dosing through essentially needle-free intradermal administration. Currently, the drug is in Phase II stage of its development for the treatment of Peanut Allergy.INP20: InnoUp Farma S.L.
INP20 is an innovative oral vaccine developed by InnoUp Farma for the treatment of peanut allergy. Utilizing proprietary nanoparticle technology, INP20 encapsulates whole peanut extract to deliver controlled release directly in the gut, minimizing systemic absorption and reducing the risk of severe allergic reactions. The formulation is designed to mask allergens from immune detection while simultaneously promoting immunomodulation by targeting antigen-presenting cells. This dual mechanism offers a promising approach to induce long-term tolerance in peanut-allergic individuals, with a clean safety profile and simplified dosing. Currently, the drug is in Phase I/II stage of its development for the treatment of Peanut Allergy.Peanut Allergy: Therapeutic Assessment
This segment of the report provides insights about the different Peanut Allergy drugs segregated based on following parameters that define the scope of the report.
Major Players in Peanut Allergy
- There are approx. 10+ key companies which are developing the therapies for Peanut Allergy. The companies which have their Peanut Allergy drug candidates in the most advanced stage, i.e. Phase III include, DBV Technologies.
The report covers around 12+ products under different phases of clinical development, like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of:
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Products have been categorized under various Molecule types, such as:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Peanut Allergy: Pipeline Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Peanut Allergy therapeutic drugs key players involved in developing key drugs.
Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peanut Allergy drugs.
Peanut Allergy Report Insights
- Peanut Allergy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Peanut Allergy drugs?
- How many Peanut Allergy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peanut Allergy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peanut Allergy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Peanut Allergy and their status?
- What are the key designations that have been granted to the emerging drugs?
- DBV Technologies
- Aravax Pty Ltd
- InnoUp Farma S.L.
- Allergy Therapeutics
- ALK-Abelló A/S
- IgGenix Australia Pty Ltd
- DBV712
- PVX-108
- INP20
- VLP Peanut
- Peanut SLIT-tablet
- IGNX001
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryPeanut Allergy - Analytical PerspectivePeanut Allergy Key CompaniesPeanut Allergy Key ProductsPeanut Allergy - Unmet NeedsPeanut Allergy - Market Drivers and BarriersPeanut Allergy - Future Perspectives and ConclusionPeanut Allergy Analyst ViewsPeanut Allergy Key CompaniesAppendix
Peanut Allergy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
DBV712: DBV Technologies
Mid Stage Products (Phase II)
PVX-108: Aravax Pty Ltd
Early Stage Products (Phase I/II)
INP20: InnoUp Farma S.L.
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- DBV Technologies
- Aravax Pty Ltd
- InnoUp Farma S.L.
- Allergy Therapeutics
- ALK-Abellà A/S
- IgGenix Australia Pty Ltd
